Related references
Note: Only part of the references are listed.Oxidative stress and schizophrenia: recent breakthroughs from an old story
Francesco E. Emiliani et al.
CURRENT OPINION IN PSYCHIATRY (2014)
A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - Results from the CandleLyte study
D. Bugarski-Kirola et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
E. M. P. Poels et al.
MOLECULAR PSYCHIATRY (2014)
Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals
C-H Lin et al.
MOLECULAR PSYCHIATRY (2014)
PREVENTION Before the break
Michele Solis
NATURE (2014)
Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: A systematic review of biomarker studies
M. J. Stuart et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2014)
Clinically meaningful biomarkers for psychosis: A systematic and quantitative review
Diana Prata et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2014)
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Iris E. Sommer et al.
SCHIZOPHRENIA BULLETIN (2014)
Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain
Kenji Hashimoto
SCHIZOPHRENIA RESEARCH (2014)
N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice
Ana P. Herrmann et al.
SCHIZOPHRENIA RESEARCH (2014)
Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia A Randomized, Double-Blind, Proof-of-Concept Study
Daniel Umbricht et al.
JAMA PSYCHIATRY (2014)
Bitopertin The Good News and Bad News
Donald C. Goff
JAMA PSYCHIATRY (2014)
Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia A Proton Magnetic Resonance Spectroscopy Study at 3 T
Juan R. Bustillo et al.
JAMA PSYCHIATRY (2014)
Redox Dysregulation in the Pathophysiology of Schizophrenia and Bipolar Disorder: Insights from Animal Models
Anita Kulak et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
The Cystine/Glutamate Antiporter System xc- in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities
Jan Lewerenz et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Is D-Cycloserine a Prodrug for D-Serine in the Brain?
Mao Horio et al.
BIOLOGICAL PSYCHIATRY (2013)
Early-Life Insults Impair Parvalbumin Interneurons via Oxidative Stress: Reversal by N-Acetylcysteine
Jan-Harry Cabungcal et al.
BIOLOGICAL PSYCHIATRY (2013)
N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study
Mehdi Farokhnia et al.
CLINICAL NEUROPHARMACOLOGY (2013)
D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy
Silvia Sacchi et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Biomarkers in Schizophrenia: A Brief Conceptual Consideration
Cynthia S. Weickert et al.
DISEASE MARKERS (2013)
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Kenji Hashimoto et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2013)
N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine
K. Sunitha et al.
FREE RADICAL RESEARCH (2013)
Up-Regulation of Neurotrophic Factors by Cinnamon and its Metabolite Sodium Benzoate: Therapeutic Implications for Neurodegenerative Disorders
Arundhati Jana et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2013)
Disruption of Shmt1 Impairs Hippocampal Neurogenesis and Mnemonic Function in Mice
Elena V. Abarinov et al.
JOURNAL OF NUTRITION (2013)
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
C. S. Weickert et al.
MOLECULAR PSYCHIATRY (2013)
Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers
Meret Martin-Facklam et al.
NEUROPSYCHOPHARMACOLOGY (2013)
EARLY DEVELOPMENTAL ELEVATIONS OF BRAIN KYNURENIC ACID IMPAIR COGNITIVE FLEXIBILITY IN ADULTS: REVERSAL WITH GALANTAMINE
K. S. Alexander et al.
NEUROSCIENCE (2013)
Neonatal Disruption of Serine Racemase Causes Schizophrenia-Like Behavioral Abnormalities in Adulthood: Clinical Rescue by D-Serine
Hiroko Hagiwara et al.
PLOS ONE (2013)
Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression
Kenji Hashimoto
PROGRESS IN NEUROBIOLOGY (2013)
Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
Virginia L. Stauffer et al.
SCHIZOPHRENIA RESEARCH (2013)
The promise of N-acetylcysteine in neuropsychiatry
Michael Berk et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor
Hsien-Yuan Lane et al.
JAMA PSYCHIATRY (2013)
N-Acetylcysteine ethyl ester (NACET): A novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential
Daniela Giustarini et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Glutamatergic Modulation of Auditory Information Processing in the Human Brain
Handan Gunduz-Bruce et al.
BIOLOGICAL PSYCHIATRY (2012)
N-Acetylcysteine Normalizes Neurochemical Changes in the Glutathione-Deficient Schizophrenia Mouse Model During Development
Joao Miguel das Neves Duarte et al.
BIOLOGICAL PSYCHIATRY (2012)
Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Thomas L. Schwartz et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Tomihisa Niitsu et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Kynurenines in the mammalian brain: when physiology meets pathology
Robert Schwarcz et al.
NATURE REVIEWS NEUROSCIENCE (2012)
Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
Daniela Alberati et al.
NEUROPHARMACOLOGY (2012)
From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
Bita Moghaddam et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Glutathione Precursor N-Acetyl-Cysteine Modulates EEG Synchronization in Schizophrenia Patients: A Double-Blind, Randomized, Placebo-Controlled Trial
Cristian Carmeli et al.
PLOS ONE (2012)
Role of Serine Racemase in Behavioral Sensitization in Mice after Repeated Administration of Methamphetamine
Mao Horio et al.
PLOS ONE (2012)
N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals
Elson Asevedo et al.
REVIEWS IN THE NEUROSCIENCES (2012)
Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine
Hongxian Chen et al.
PSYCHOPHARMACOLOGY (2012)
Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
Daniel C. Javitt et al.
SCHIZOPHRENIA BULLETIN (2012)
NMDA Receptor and Schizophrenia: A Brief History
Joseph T. Coyle
SCHIZOPHRENIA BULLETIN (2012)
Plasma levels of D-serine in Brazilian individuals with schizophrenia
Marilia A. Calcia et al.
SCHIZOPHRENIA RESEARCH (2012)
Effects of the Antioxidant Sulforaphane on Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Phencyclidine Administration
Yumi Shirai et al.
Clinical Psychopharmacology and Neuroscience (2012)
Recent Advances in Potential Therapeutic Drugs for Cognitive Impairment in Schizophrenia
Taisuke Yoshida et al.
CURRENT PSYCHIATRY REVIEWS (2012)
Magnetic Resonance Spectroscopy Study of the Antioxidant Defense System in Schizophrenia
Daisuke Matsuzawa et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes
Ikwunga Wonodi et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
alpha 7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia
Masatomo Ishikawa et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Recent Advances in the Discovery of D-Amino Acid Oxidase Inhibitors and Their Therapeutic Utility in Schizophrenia
Dana V. Ferraris et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
Kenji Hashimoto
CURRENT PHARMACEUTICAL DESIGN (2011)
Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Norbert Mueller et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice
Mao Horio et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine
Kathleen S. Alexander et al.
PSYCHOPHARMACOLOGY (2011)
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Korrapati V. Sathyasaikumar et al.
SCHIZOPHRENIA BULLETIN (2011)
Translating Glutamate: From Pathophysiology to Treatment
Daniel C. Javitt et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial
G. Paul Amminger et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Guochuan E. Tsai et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
Hsien-Yuan Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia
Emmanuel Pinard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Analysis of strain-dependent prepulse inhibition points to a role for Shmt1 (SHMT1) in mice and in schizophrenia
Motoko Maekawa et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Redox Dysregulation Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations, and Related Behaviors
Pascal Steullet et al.
JOURNAL OF NEUROSCIENCE (2010)
Comments on 'The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia'
Kenji Hashimoto
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
The neurobiology of D-amino acid oxidase and its involvement in schizophrenia
L. Verrall et al.
MOLECULAR PSYCHIATRY (2010)
Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study
Yukihiko Shirayama et al.
NEUROIMAGE (2010)
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Stephen F. Traynelis et al.
PHARMACOLOGICAL REVIEWS (2010)
Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions
Kenji Hashimoto
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2010)
Developmental Vitamin D Deficiency and Risk of Schizophrenia: A 10-Year Update
John J. McGrath et al.
SCHIZOPHRENIA BULLETIN (2010)
High dose D-serine in the treatment of schizophrenia
Joshua T. Kantrowitz et al.
SCHIZOPHRENIA RESEARCH (2010)
Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine
Kenji Hashimoto et al.
BIOLOGICAL PSYCHIATRY (2009)
Can the Sigma-1 Receptor Agonist Fluvoxamine Prevent Schizophrenia?
Kenji Hashimoto
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2009)
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar et al.
NATURE (2009)
Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation
Stephen J. Wood et al.
NEUROBIOLOGY OF DISEASE (2009)
Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients
Monia Raffa et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2009)
D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats
Jun-Ichi Karasawa et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Sarcosine (N-Methylglycine) treatment for acute schizophrenia: A randomized, double-blind study
Hsien-Yuan Lane et al.
BIOLOGICAL PSYCHIATRY (2008)
Regarding “N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial”
Kenji Hashimoto
BIOLOGICAL PSYCHIATRY (2008)
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
Michael Berk et al.
BIOLOGICAL PSYCHIATRY (2008)
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine
Kenji Hashimoto et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
Synthesis and biological evaluation of D-amino acid oxidase inhibitors
Dana Ferraris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
NMDA- and β-Amyloid1-42-Induced Neurotoxicity Is Attenuated in Serine Racemase Knock-Out Mice
Ran Inoue et al.
JOURNAL OF NEUROSCIENCE (2008)
Neurophysiological biomarkers for drug development in schizophrenia
Daniel C. Javitt et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study
Daisuke Matsuzawa et al.
PLOS ONE (2008)
Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine
David A. Baker et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
Suzie Lavoie et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Increased levels of glutamate in brains from patients with mood disorders
Kenji Hashimoto et al.
BIOLOGICAL PSYCHIATRY (2007)
Impaired glutathione synthesis in schizophrenia:: Convergent genetic and functional evidence
Rene Gysin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia
Inna Bendikov et al.
SCHIZOPHRENIA RESEARCH (2007)
BDNF variant linked to anxiety-related behaviors
Kenji Hashimoto
BIOESSAYS (2007)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to clozapine for the treatment of schizophrenia
Hsien-Yuan Lane et al.
BIOLOGICAL PSYCHIATRY (2006)
Schizophrenia and oxidative stress:: Glutamate cysteine ligase modifier as a susceptibility gene
Mirjana Tosic et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder
CL Miller et al.
BRAIN RESEARCH (2006)
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia
LK Nilsson et al.
SCHIZOPHRENIA RESEARCH (2005)
Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T:: application to schizophrenia
M Terpstra et al.
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE (2005)
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia - A randomized, double-blind, placebo-controlled study
HY Lane et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels
K Yamada et al.
BIOLOGICAL PSYCHIATRY (2005)
Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients
K Hashimoto et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2005)
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
U Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2005)
Dysfunction of Glia-Neuron Communication in Pathophysiology of Schizophrenia
Kenji Hashimoto et al.
CURRENT PSYCHIATRY REVIEWS (2005)
Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients
Kenji Hashimoto et al.
BMC PSYCHIATRY (2005)
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
HJ Tuominen et al.
SCHIZOPHRENIA RESEARCH (2005)
Critical role of brain-derived neurotrophic factor in mood disorders
K Hashimoto et al.
BRAIN RESEARCH REVIEWS (2004)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to antipsychotics for the treatment of schizophrenia
GC Tsai et al.
BIOLOGICAL PSYCHIATRY (2004)
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis
U Heresco-Levy et al.
SCHIZOPHRENIA RESEARCH (2004)
Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine
G Fukami et al.
BRAIN RESEARCH (2004)
Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine
K Hashimoto et al.
NEUROPSYCHOPHARMACOLOGY (2004)
The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
JT Coyle et al.
PSYCHOPHARMACOLOGY (2004)
Decreased serum levels of D-serine in patients with schizophrenia - Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia
K Hashimoto et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Genes for schizophrenia? Recent findings and their pathophysiological implications
PJ Harrison et al.
LANCET (2003)
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia
I Chumakov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
S Erhardt et al.
NEUROSCIENCE LETTERS (2001)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
Metabolism and functions of glutathione in brain
R Dringen
PROGRESS IN NEUROBIOLOGY (2000)
Schizophrenia:: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
KQ Do et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2000)
Share Paper
